Clinical trials: Second Cancer
Stomach Neoplasms, Gastric Cancer
A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer
English Translation (for ClinicalTrials.gov Patient-Friendly Summary): This is a Phase II clinical trial for patients with advanced gastric cancer (stomach cancer).
- Trial name
- NCT07819019
- Testing
- Fruquintinib, Sintilimab, Irinotecan Hydrochloride Liposome Injection (II)
- Volunteers
- 20 people
- Sponsor
- Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Pregnancy Trimester, First, Pregnancy Trimester, Second
Clinical Trial to Assess the Influence of Gestational Stage and Maternal Age on Arterial Stiffness of the Mother
This is a single-centre, open, parallel-group study with three age groups; no study medication or intervention will be provided. This is a longitudinal follow-up of physiological parameters.
- Conditions
- Pregnancy Trimester, First, Pregnancy Trimester, Second, Pregnancy Trimester, Third
- Trial name
- NCT00180219
- Where
- Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders
This clinical trial is studying how well giving fludarabine phosphate and melphalan together with total-body irradiation followed by donor stem cell transplant works in treating patients with hematologic cancer or bone marrow…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00856388
- Testing
- fludarabine phosphate, melphalan, total-body irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Roswell Park Cancer Institute
Esophageal Cancer
S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as cetuximab may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00096031
- Testing
- cetuximab
- Where
- 152 sites in United States
- Volunteers
- 63 people
- Sponsor
- SWOG Cancer Research Network
Thrombocytopenia Chemotherapy Induced
Romiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
This study aims to evaluate the efficacy and safety of Romiplostim N01 for Injection administered as secondary prophylaxis in breast cancer patients with chemotherapy-induced thrombocytopenia (CIT).
- Trial name
- NCT07771881
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Mantle Cell Lymphoma
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
This is a Phase I/II multicenter, open-label, dose-escalation study of rituximab, bortezomib, and lenalidomide in the first-line or second-line treatment of patients with Mantle Cell Lymphoma (MCL).
- Trial name
- NCT00633594
- Testing
- Rituximab, Bortezomib, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- SCRI Development Innovations, LLC
Liver Metastases, Hepatic Metastases
Therapeutic Efficacy and Safety of Ultrasound-Guided Microwave Ablation for Hepatic Metastatic Nodules
The liver is one of the most common organs where cancer cells spread (metastasize) from other parts of the body, especially from gastrointestinal cancers such as colorectal cancer.
- Conditions
- Liver Metastases, Hepatic Metastases, Secondary Malignant Neoplasm of Liver, Colorectal Cancer Metastatic
- Trial name
- NCT07871253
- Testing
- Ultrasound-Guided Microwave Ablation
- Volunteers
- 30 people
- Sponsor
- Assiut University
Prostatic Neoplasms
Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden
This study is conducted to obtain information about prostate cancer patients with bone metastases before the end of 2013. The incidence of second primary malignancies and overall survival in patients with castration resistant…
- Trial name
- SMARCOS (NCT02963675)
- Where
- Sweden
- Volunteers
- 15,953 people
- Sponsor
- Bayer
Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7)
CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
This phase 2 clinical trial studies how well CPX-351 (liposomal cytarabine-daunorubicin) works in treating patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
- Conditions
- Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)
- Trial name
- NCT02019069
- Testing
- liposomal cytarabine-daunorubicin CPX-351
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rondeep Brar
Gastric Cancer, Gastroesophageal Junction Cancer
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
This study will evaluate overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.
- Trial name
- NCT01813253
- Testing
- Irinotecan, Nimotuzumab
- Where
- 37 sites in Japan, South Korea and 1 more
- Volunteers
- 400 people
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd.
Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1/L1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three…
- Trial name
- NCT07022301
- Testing
- sintilimab combined with anlotinib
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Advanced Triple-Negative Breast Cancer
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
- Trial name
- NCT03254654
- Testing
- Vinorelbine, Apatinib
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Fudan University
Pilonidal Sinus
Primary Wound Closure Using a Limberg Flap Versus Secondary Wound Healing Following Pilonidal Sinus Excision
To compare primary wound closure using a limberg flap with secondary (p.s.) wound healing following excision of a pilonidal sinus.
- Trial name
- NCT01889394
- Testing
- secondary wound healing, primary wound closure using a limberg flap
- Where
- 3 sites in Switzerland
- Volunteers
- 102 people
- Sponsor
- Kantonsspital Liestal
Colorectal Cancer
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer.
- Trial name
- MRD (NCT05210283)
- Testing
- MRD
- Where
- 32 sites in United States, Canada
- Volunteers
- 1,017 people
- Sponsor
- Exact Sciences Corporation
Pilonidal Sinus, Pilonidal Cyst
Karydakis Procedure Versus Excision With Healing by Secondary Intention (EHSI) in Sacrococcygeal Pilonidal Sinus
Recurrence, Complications, Work-off date, Healing time and Patients Willingness in Karydakis Technique for Treatment of Sacrococcygeal Pilonidal Sinus versus Healing by Secondary Intention (EHSI) Technique in Imam Khomeini…
- Trial name
- NCT00716937
- Testing
- karydakis flap, laying open
- Where
- Iran
- Volunteers
- 321 people
- Sponsor
- Tehran University of Medical Sciences
HER2 Expression / Amplification in Patients With Biliary Tract Cancer
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
This study was to evaluate the efficacy and safety of SHR-A1811 in patients with locally advanced unresectable or recurrent metastatic BTC with HER2 expression / amplification who failed first-line or second-line systemic…
- Trial name
- NCT06413745
- Testing
- SHR-A1811
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Lung Carcinoma
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
This is an open, multi-cohort, exploratory phase II study on the safety and efficacy of TQB3616 combined with Anlotinib hydrochloride capsules or standard chemotherapy in the treatment of advanced lung cancer.
- Trial name
- NCT04924192
- Testing
- TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection
- Where
- 7 sites in China
- Volunteers
- 21 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Leukemia, Lymphoma
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
RATIONALE: Nelfinavir mesylate and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Leukemia, Lymphoma, Mature T-cell and Nk-cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT01164709
- Testing
- bortezomib, nelfinavir mesylate
- Where
- 4 sites in Switzerland
- Volunteers
- 18 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer, Cancer
Breast Re-irradiation After Second Ipsilateral Lumpectomy
The purpose of this research study is to test the safety and possible harms of treating breast cancer with reirradiation, after breast surgery.
- Conditions
- Breast Cancer, Cancer, Cancer of the Breast, HER2-negative Breast Cancer
- Trial name
- BRASIL (NCT06867484)
- Testing
- Intensity modulated radiation therapy (IMRT)
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Youssef Zeidan
Cancer
A Study of TS-1, Cisplatin (CDDP) and RAD001 (Everolimus)
Hypothesis: The addition of RAD001 to TS-1/CDDP is safe and can improved the efficacy of TS-1/CDDP. The rationale for combining RAD001 with TS-1/CDDP are: 1.
- Trial name
- NCT01096199
- Testing
- TS-ONE, Cisplatin, RAD001
- Where
- Singapore
- Volunteers
- 35 people
- Sponsor
- National University Hospital, Singapore